

CSD/BSE&NSE/PR/2025-26
August 12, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Press Release

We enclose herewith press release viz. “Cohance Lifesciences Announces USD 10 mn Investment in cGMP Bioconjugation Suite at NJ Bio, Princeton, NJ, U.S. to Accelerate ADC Innovation”.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com





Cohance Lifesciences Announces USD 10 mn Investment in cGMP Bioconjugation Suite at NJ Bio, Princeton, NJ, U.S. to Accelerate ADC Innovation

- Expansion will significantly enhance NJ Bio's cGMP bioconjugation capabilities, enabling supply of full ADCs up to Phase 2b clinical studies.
- Strengthens end-to-end integrated offering in Antibody-Drug Conjugates, combining payload-linker synthesis and bioconjugation under one roof.

Hyderabad, India / Princeton, NJ, 12th August, 2025

Cohance Lifesciences (with its subsidiaries, hereafter referred to as “Cohance”), a leading global Contract Research, Development & Manufacturing Organization (CRDMO), announced a strategic investment of **USD 10** million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio. Aligned with the Company's long-term strategy, this investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply. The build-out of a state-of-the-art, cGMP compliant bioconjugation suite at NJ Bio's Princeton, New Jersey facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions - from early-phase payload-linker synthesis through to complete ADC manufacturing for clinical supply.

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline. The engagement spans early-phase payload-linker development—already underway—and will advance to cGMP bioconjugation upon commissioning of the new suite. This collaboration underscores the customer's confidence in NJ Bio's ability to deliver complex chemistry solutions and end-to-end ADC manufacturing support for Phase 1 and Phase 2 clinical studies.

The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs, sufficient for clinical requirements once the program transitions to cGMP production in the expanded facility. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Beyond this, NJ Bio is in advanced discussions with three to four additional customers whose ADC programs are expected to transition to cGMP manufacturing in alignment with the commissioning of the expanded suite. Recently NJ Bio has expanded its linker-payload capabilities with a dedicated lab, completing one GMP campaign with two more underway.

The global ADC market, valued in the billions, is experiencing robust growth driven by rising cancer incidence and increasing demand for targeted immuno-oncology therapies. NJ Bio's comprehensive single-site CRDMO model-integrating payload-linker synthesis, bioconjugation chemistry, process optimization, analytical characterization, and clinical manufacturing-aligns with the growing preference among global innovators for seamless, end-to-end execution under one roof.

Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: *"This investment marks a pivotal milestone in strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster. As a global CRDMO, we're excited to leverage our strong presence in both the U.S. and India to deliver differentiated value to innovators worldwide."*

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies. In FY25, revenue was INR 26 billion (~USD 313 million) with 33.6% adjusted EBITDA margins, with the CDMO business—driven largely by its commercial partnerships with global innovators.

-ENDS-

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@cohance.com

Gavin Desa / Rishab Barar
CDR India
Tel: +91 98206 37649/ +91 77770 35061
Email: gavin@cdr-india.com
rishab@cdr-india.com

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com